BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$201.15
-1.80 (-0.89%)
▼
5d:
+0.5%
30d:
-6.93%
90d:
+7.53%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 5.4/10
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BIIB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: BIIB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$377.84
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$234.61
14.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $201.15, which is considered slightly high relative to its 30-day fair value range of $197.79 to $210.90. The stock's valuation (Forward PE: 12.2) is in line with its historical norms (11.7). At these levels, the market is pricing in 1.5% annual earnings growth.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is currently testing key support at $196.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIIB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $233.87 (+15.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is currently testing key support at $196.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BIIB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $233.87 (+15.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$197.79 -
$210.90
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($233.87)
- BULLISH: Expecting earnings turnaround to 1.5% growth with 3.4% revenue growth
Trading Range Analysis
30-Day Trading Range
$197.79 -
$210.90
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$196.92
Resistance Level
$218.59
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.24
Wall Street Target
$233.87
(+15.2%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
-84.8%
Profit Margin
8.3%
Valuation Premium vs History
+1.5% premium
PE vs Historical
12.2 vs 11.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$205.99
(+2%)
2-Year Target
$209.08
(+3%)
3-Year Target
$212.22
(+5%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$202.89
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 33.1%)
$811.16
(+300%)
Base:
(SPY PE: 12.2, Growth: 33.1%)
$478.87
(+136%)
Bear:
(PE: 10.4, Growth: 33.1%)
$407.04
(+101%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 36.93 | Current EPS (TTM): $5.63
Bull Case
$457.45
(+125%)
Analyst growth 100.0%, PE expands to 40.6
Base Case
$415.86
(+105%)
Market implied 100.0%, PE stable at 36.9
Bear Case
$141.39
(-30%)
Severe decline -20.0%, PE contracts to 31.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 2:25 PM ET
Data refreshes hourly during market hours. Next update: 3:25 PM
Data refreshes hourly during market hours. Next update: 3:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Ro Khanna
SELL
2026-02-06
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 56 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 52 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$135 | 56 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
